NCT00942734 2025-05-01
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
M.D. Anderson Cancer Center
University of Chicago
University of Chicago
Yonsei University
National Cancer Institute (NCI)